Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $10.80.

A number of equities research analysts recently commented on RGLS shares. Canaccord Genuity Group increased their price target on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, June 25th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Friday, September 6th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 9th. Finally, Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth $136,000. Renaissance Technologies LLC boosted its position in shares of Regulus Therapeutics by 56.4% in the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 42,600 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 38,529 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the 2nd quarter worth $352,000. Finally, Opaleye Management Inc. bought a new position in shares of Regulus Therapeutics in the 1st quarter worth $490,000. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Stock Performance

NASDAQ RGLS opened at $1.61 on Monday. Regulus Therapeutics has a one year low of $1.08 and a one year high of $3.79. The stock’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $2.04.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). As a group, equities research analysts forecast that Regulus Therapeutics will post -0.8 EPS for the current fiscal year.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.